Literature DB >> 17903613

Melanocyte receptors: clinical implications and therapeutic relevance.

J Andrew Carlson1, Gerald P Linette, Andrew Aplin, Bernard Ng, Andrzej Slominski.   

Abstract

The activation or the inhibition of melanocyte-specific receptors offers novel means of augmenting normal melanocyte function, skin color, and photoprotection, or treating melanocytic disorders, namely at this time, metastatic melanoma. Melanocyte-specific receptors include melanocortin-1 (MCR1) and melatonin receptors. Other receptors that play an important role in melanoma progression are G-protein couple receptors such as Frizzled 5 and receptor tyrosine kinases such as c-Kit and hepatocyte growth factor (HGF) receptor. These receptors activate two crucial cell-signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT, integral to melanoma cell survival, and can serve as targets for therapy of disseminated melanoma. Activation of death receptors is another pathway that can be exploited with targeted therapeutics to control advanced melanoma. This article reviews the current understanding of melanocyte receptors, their agonists and inhibitors, and their potential to treat the melanocytic pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17903613      PMCID: PMC2732336          DOI: 10.1016/j.det.2007.06.005

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  139 in total

1.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

Authors:  Lila Adnane; Pamela A Trail; Ian Taylor; Scott M Wilhelm
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.

Authors:  Yann Berger; Catherine Chapuis Bernasconi; Lucienne Juillerat-Jeanneret
Journal:  Exp Biol Med (Maywood)       Date:  2006-06

3.  BRAF alterations are associated with complex mutational profiles in malignant melanoma.

Authors:  Maria Daniotti; Maria Oggionni; Tiziana Ranzani; Viviana Vallacchi; Valentina Campi; Delia Di Stasi; Gabriella Della Torre; Federica Perrone; Chiara Luoni; Simona Suardi; Milo Frattini; Silvana Pilotti; Andrea Anichini; Gabrina Tragni; Giorgio Parmiani; Marco A Pierotti; Monica Rodolfo
Journal:  Oncogene       Date:  2004-08-05       Impact factor: 9.867

Review 4.  Targeting melanocortin receptors as potential novel therapeutics.

Authors:  Stephen J Getting
Journal:  Pharmacol Ther       Date:  2006-02-20       Impact factor: 12.310

5.  Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B.

Authors:  Carola Berking; Richelle Takemoto; Kapaettu Satyamoorthy; Takahashi Shirakawa; Malihe Eskandarpour; Johan Hansson; Patricia A VanBelle; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Reciprocal regulation of MelCAM and AKT in human melanoma.

Authors:  Gang Li; Jiri Kalabis; Xiaowei Xu; Friedegund Meier; Masahiro Oka; Thomas Bogenrieder; Meenhard Herlyn
Journal:  Oncogene       Date:  2003-10-09       Impact factor: 9.867

Review 7.  Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents.

Authors:  Brian J Nickoloff; Barbara A Osborne; Lucio Miele
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

Review 8.  Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium.

Authors:  Alex N Eberle; Sylvie Froidevaux
Journal:  J Mol Recognit       Date:  2003 Sep-Oct       Impact factor: 2.137

9.  p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.

Authors:  Jian-Zhong Qin; Lawrence Stennett; Patricia Bacon; Barbara Bodner; Mary J C Hendrix; Richard E B Seftor; Elisabeth A Seftor; Naira V Margaryan; Pamela M Pollock; Amy Curtis; Jeffrey M Trent; Frank Bennett; Lucio Miele; Brian J Nickoloff
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

10.  A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma.

Authors:  J A Halsall; J E Osborne; L Potter; J H Pringle; P E Hutchinson
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  17 in total

1.  Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment.

Authors:  Nabila Brabez; Ronald M Lynch; Liping Xu; Robert J Gillies; Gerard Chassaing; Solange Lavielle; Victor J Hruby
Journal:  J Med Chem       Date:  2011-10-03       Impact factor: 7.446

2.  The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi.

Authors:  Song Lu; Andrzej Slominski; Sung-Eun Yang; Christine Sheehan; Jeffrey Ross; J Andrew Carlson
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

Review 3.  Applications of nanotechnology in dermatology.

Authors:  Lisa A DeLouise
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

4.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Authors:  Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  Genome-wide transcriptome analysis of human epidermal melanocytes.

Authors:  Kirk D Haltaufderhyde; Elena Oancea
Journal:  Genomics       Date:  2014-10-30       Impact factor: 5.736

6.  Inhibitory effects of Lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action.

Authors:  Liping Wang; Huiying Duan; Yishan Wang; Kun Liu; Peng Jiang; Zhen Qu; Kazumi Yagasaki; Guoying Zhang
Journal:  Cytotechnology       Date:  2010-07-04       Impact factor: 2.058

7.  Cooling skin cancer: menthol inhibits melanoma growth. Focus on "TRPM8 activation suppresses cellular viability in human melanoma".

Authors:  Andrzej Slominski
Journal:  Am J Physiol Cell Physiol       Date:  2008-08       Impact factor: 4.249

8.  Current concepts of metastasis in melanoma.

Authors:  Blazej Zbytek; J Andrew Carlson; Jacqueline Granese; Jeffrey Ross; Martin C Mihm; Andrzej Slominski
Journal:  Expert Rev Dermatol       Date:  2008-10

9.  Ras controls melanocyte expansion during zebrafish fin stripe regeneration.

Authors:  Yoonsung Lee; Gregory Nachtrab; Pai W Klinsawat; Danyal Hami; Kenneth D Poss
Journal:  Dis Model Mech       Date:  2010-05-18       Impact factor: 5.758

10.  Knowledge building insights on biomarkers of arsenic toxicity to keratinocytes and melanocytes.

Authors:  Raphael D Isokpehi; Udensi K Udensi; Matthew N Anyanwu; Andreas N Mbah; Matilda O Johnson; Kafui Edusei; Michael A Bauer; Roger A Hall; Omotayo R Awofolu
Journal:  Biomark Insights       Date:  2012-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.